Adverse effects: headache · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: headache compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: urinary incontinence · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: urinary incontinence compared with placebo (very low certainty).
1 finding from 1 review
Somnolence · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: drowsiness compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: palpitations · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: palpitations compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: dry mouth · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: dry mouth compared with placebo (very low certainty).
1 finding from 1 review
QoL · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months)
SoF1. Change in QoL short-term (mean Beck Depression Inventory, 0-63, lower better): this single study narratively reported that both intervention and placebo participants were less depressed at trial completion, but…
1 study · 37 participants
Very low
Physician Global Assessment (Thongprasom score) · People with erosive oral lichen planus
0.1% triamcinolone acetonide in orabase showed no clear difference in physician Global Assessment (Thongprasom score) compared with ciclosporin solution; GRADE not reported.
1 finding from 1 review
Pain reduction (VAS 0-100) · People with erosive oral lichen planus
0.1% triamcinolone acetonide in orabase led to higher pain reduction (VAS 0-100) compared with ciclosporin solution; GRADE not reported.
1 finding from 1 review
Betamethasone (systemic corticosteroid) vs Placebo or no treatment
Outcome not reported · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
The review found no eligible studies for this question.
1 finding from 1 review
Side effects · People with erosive oral lichen planus
1 finding from 1 review
Hydrocortisone (systemic corticosteroid) vs Placebo or no treatment
Outcome not reported · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
The review found no eligible studies for this question.
1 finding from 1 review
Severity of oral/mucosal burning pain/sensation · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Quality of life · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Patients in the propolis group self-reported a significant improvement in their quality of life (P=0.03), based on volunteered statements of self-reported improvement.
1 study · 19 participants
GRADE not reported
Mean number of lesions over treatment period · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Bee propolis (one 500 mg capsule per day) showed no clear difference in mean number of lesions over treatment period compared with placebo; GRADE not reported.
1 finding from 1 review
Reduction of outbreaks (expected vs observed ulcers) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
The authors report a statistically significant difference in the reduction of outbreaks based on the difference between expected and observed number of ulcers (Fisher's exact test, one sided, P=0.04).
1 study · 19 participants
GRADE not reported
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether hydrocortisone plus hyaluronidase (intralesional) changes maximal mouth opening (interincisal distance) compared with placebo or no active treatment (very low certainty).
1 finding from 1 review
Beclometasone dipropionate (systemic corticosteroid) vs Placebo or no treatment
Outcome not reported · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
The review found no eligible studies for this question.
1 finding from 1 review
Time to resolution of first ulcer (days) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Prednisone (oral, commencing 25 mg with phased dose reduction over 2… led to lower time to resolution of first ulcer (days) compared with placebo; GRADE not reported.
1 finding from 1 review